Products for Research Use Only
RegisterLogin

Zurletrectinib

CAT: 0804-HY-148811-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-148811-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Zurletrectinib is a brain-penetrant, orally active TRK inhibitor (TRKA IC50 = 0.81 nM; TRKB IC50 = 0.145 nM; TRKC IC50 = 0.184 nM) . Zurletrectinib exhibits stronger activity as a consequence of its augmented binding affinity for TRK kinases. Zurletrectinib exhibits higher activity against most TRK inhibitor resistance mutations (13 out of 18 mutations) . Zurletrectinib can be used for the study of glioma[1].
CAS Number
2403703-30-8
Product Name Alternative
ICP-723
UNSPSC
12352005
Target
C-Met/HGFR; Trk Receptor
Type
Reference compound
Related Pathways
Neuronal Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zurletrectinib.html
Purity
99.32
Solubility
DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1NC2=C3N=C(N4[C@@](C[C@@](F)([H])C4)([H])C5=CC(F)=CN=C5O[C@](C)([H])CN1)C=CN3N=C2
Molecular Formula
C19H19F2N7O2
Molecular Weight
415.40
References & Citations
[1]Kong NX, et al. Preparation of the heterocyclic compounds as trk inhibitor: World Intellectual Property Organization, WO2020001415. 2020-01-02.|[2]WHO Drug Information-World Health Organization (WHO) .|[3]Roa P, et al. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents. Br J Cancer. 2024 Aug;131 (3) :601-610.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
TrkA; TrkB; TrkC

Alternative Products

CatalogName
T69650-01Zurletrectinib

Popular Products